Payment overview · 2025
General Payments
$587.87
24 reported records · 12 companies
Healthcare provider profile · identity verified
Ibrahim M Almeky, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINGSTON, PA · NPI 1750477139
Verified facts
What the public records show
CMS Open Payments records show Ibrahim M Almeky, MD received $587.87 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rinvoq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Lokelma by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.70 | 23.4% | 9 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $122.98 | 20.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $103.96 | 17.7% | 4 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $57.70 | 9.8% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $32.67 | 5.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.91 | 4.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.99 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.60 | 3.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.34 | 2.6% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.25 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.08 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.69 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.87 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $122.98 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $122.98 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $103.96 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.51 | 5 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $57.70 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $57.70 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2336 | 175 |
| Furosemide | Furosemide | 1641 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1556 | 113 |
| Potassium Chloride | Potassium Chloride | 1346 | 105 |
| Gabapentin | Gabapentin | 1310 | 96 |
| Eliquis | Apixaban | 1264 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1190 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 925 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 924 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 885 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 874 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 736 | 52 |
| Lisinopril | Lisinopril | 702 | 58 |
| Sertraline Hcl | Sertraline Hcl | 682 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 650 | 46 |
| Mirtazapine | Mirtazapine | 609 | 57 |
| Donepezil Hcl | Donepezil Hcl | 566 | 37 |
| Simvastatin | Simvastatin | 512 | 33 |
| Metformin Hcl | Metformin Hcl | 489 | 51 |
| Losartan Potassium | Losartan Potassium | 487 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 480 | 33 |
| Allopurinol | Allopurinol | 473 | 28 |
| Trazodone Hcl | Trazodone Hcl | 469 | 35 |
| Carvedilol | Carvedilol | 461 | 32 |
| Levetiracetam | Levetiracetam | 397 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 24 |
| Midodrine Hcl | Midodrine Hcl | 356 | 30 |
| Omeprazole | Omeprazole | 337 | 64 |
| Tradjenta | Linagliptin | 334 | 20 |
| Memantine Hcl | Memantine Hcl | 321 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 305 | 16 |
| Finasteride | Finasteride | 288 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 24 |
| Famotidine | Famotidine | 275 | 26 |
| Spironolactone | Spironolactone | 260 | 23 |
| Aripiprazole | Aripiprazole | 245 | 17 |
| Baclofen | Baclofen | 242 | 23 |
| Torsemide | Torsemide | 237 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 227 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 220 | 17 |
| Divalproex Sodium | Divalproex Sodium | 218 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 206 | 26 |
| Prednisone | Prednisone | 199 | 70 |
| Warfarin Sodium | Warfarin Sodium | 199 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 196 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 193 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 187 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 187 | 44 |
| Xarelto | Rivaroxaban | 187 | suppressed |
| Sucralfate | Sucralfate | 183 | 24 |
| Metformin Hcl Er | Metformin Hcl | 175 | 13 |
| Topiramate | Topiramate | 175 | suppressed |
| Jardiance | Empagliflozin | 173 | 26 |
| Ezetimibe | Ezetimibe | 170 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 168 | 13 |
| Olanzapine | Olanzapine | 159 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 158 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 156 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 153 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 148 | suppressed |
| Digoxin | Digoxin | 145 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 142 | 70 |
| Montelukast Sodium | Montelukast Sodium | 132 | 13 |
| Alendronate Sodium | Alendronate Sodium | 129 | suppressed |
| Metolazone | Metolazone | 125 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 119 | 20 |
| Propranolol Hcl | Propranolol Hcl | 118 | suppressed |
| Myrbetriq | Mirabegron | 117 | suppressed |
| Glipizide | Glipizide | 111 | 11 |
| Labetalol Hcl | Labetalol Hcl | 108 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 107 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 106 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 102 | 57 |
| Oxybutynin Chloride | Oxybutynin Chloride | 102 | suppressed |
| Cephalexin | Cephalexin | 101 | 33 |
| Calcitriol | Calcitriol | 100 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 100 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 98 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 98 | 25 |
| Venlafaxine Hcl | Venlafaxine Hcl | 97 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 94 | suppressed |
| Januvia | Sitagliptin Phosphate | 94 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 93 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 92 | suppressed |
| Brilinta | Ticagrelor | 91 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 89 | suppressed |
| Atenolol | Atenolol | 83 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | suppressed |
| Lamotrigine | Lamotrigine | 82 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 82 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | suppressed |
| Acetic Acid | Acetic Acid | 77 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 77 | 36 |
| Risperidone | Risperidone | 76 | 15 |
| Azithromycin | Azithromycin | 75 | 46 |
| Enalapril Maleate | Enalapril Maleate | 75 | suppressed |
| Trulicity | Dulaglutide | 74 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 71 | 16 |
| Novolog Flexpen | Insulin Aspart | 71 | 24 |
| Bupropion Xl | Bupropion Hcl | 69 | 11 |
| Dexamethasone | Dexamethasone | 67 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 65 | suppressed |
| Methimazole | Methimazole | 65 | suppressed |
| Xifaxan | Rifaximin | 65 | suppressed |
| Dutasteride | Dutasteride | 62 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 62 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 42 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 60 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Budesonide | Budesonide | 59 | 13 |
| Lactulose | Lactulose | 59 | 23 |
| Sodium Chloride | 0.9 % Sodium Chloride | 59 | 37 |
| Nortriptyline Hcl | Nortriptyline Hcl | 57 | suppressed |
| Paliperidone Er | Paliperidone | 56 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 56 | suppressed |
| Novolog | Insulin Aspart | 55 | 22 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 54 | suppressed |
| Klor-Con 10 | Potassium Chloride | 54 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Humalog | Insulin Lispro | 53 | 14 |
| Vancomycin Hcl | Vancomycin Hcl | 53 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 27 |
| Fluconazole | Fluconazole | 51 | 28 |
| Haloperidol | Haloperidol | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 11 |
| Lithium Carbonate | Lithium Carbonate | 50 | suppressed |
| Rybelsus | Semaglutide | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 45 | suppressed |
| Ozempic | Semaglutide | 44 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 23 |
| Methotrexate | Methotrexate Sodium | 42 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 42 | 21 |
| Admelog Solostar | Insulin Lispro | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Insulin Lispro | Insulin Lispro | 41 | 22 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 14 |
| Nystatin | Nystatin | 38 | 25 |
| Sodium Chloride | Sodium Chloride 0.45 % | 38 | 28 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Calcium Acetate | Calcium Acetate | 34 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 34 | suppressed |
| Scopolamine | Scopolamine | 34 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 33 | suppressed |
| Erythromycin | Erythromycin Base | 33 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 31 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 30 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 22 |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Spritam | Levetiracetam | 29 | suppressed |
| Roflumilast | Roflumilast | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 14 |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Alogliptin | Alogliptin Benzoate | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Hydroxyurea | Hydroxyurea | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 24 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 14 |
| Silver Sulfadiazine | Silver Sulfadiazine | 23 | suppressed |
| Acetazolamide | Acetazolamide | 22 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Meropenem | Meropenem | 21 | suppressed |
| Nystop | Nystatin | 21 | 11 |
| Ssd | Silver Sulfadiazine | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | 12 |
| Rinvoq | Upadacitinib | 19 | suppressed |
| Admelog | Insulin Lispro | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Budesonide Ec | Budesonide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clozapine | Clozapine | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Pulmicort Flexhaler | Budesonide | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 15 | 12 |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.87 · 24 records | Novo Nordisk Inc | AUSTEDO XR, Cologuard Collection Kit, FANAPT, FARXIGA, Flexitouch Plus, INGREZZA, MAVYRET, Nimbl, OPSUMIT, PURAPLY WOUND MATRIX, ULTOMIRIS, UPTRAVI, Vest Therapy Und, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error